MX2009009320A - Uso de antagonistas de lhrh para el tratamiento de sintomas del tracto urinario inferior, en particular vejiga hiperactiva y/o hiperactividad detrusora. - Google Patents

Uso de antagonistas de lhrh para el tratamiento de sintomas del tracto urinario inferior, en particular vejiga hiperactiva y/o hiperactividad detrusora.

Info

Publication number
MX2009009320A
MX2009009320A MX2009009320A MX2009009320A MX2009009320A MX 2009009320 A MX2009009320 A MX 2009009320A MX 2009009320 A MX2009009320 A MX 2009009320A MX 2009009320 A MX2009009320 A MX 2009009320A MX 2009009320 A MX2009009320 A MX 2009009320A
Authority
MX
Mexico
Prior art keywords
overactive bladder
urinary tract
detrusor overactivity
lower urinary
treatment
Prior art date
Application number
MX2009009320A
Other languages
English (en)
Inventor
Juergen Engel
Oliver Bauer
Original Assignee
Aeterna Zentaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aeterna Zentaris Gmbh filed Critical Aeterna Zentaris Gmbh
Publication of MX2009009320A publication Critical patent/MX2009009320A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención proporciona por lo menos un antagonista de LHRH para uso en la preparación de un medicamento para el tratamiento o profilaxis de por lo menos un síntoma del tracto urinario inferior en mamíferos, en donde por lo menos un síntoma del tracto urinario inferior se selecciona del grupo que consiste de: "incontinencia urinaria, incontinencia para miccionar, vejiga hiperactiva, vejiga hiperactiva idiopatica, vejiga hiperactiva neurogénica, hiperactividad detrusora, hiperactividad detrusora idiopática, hiperactividad detrusora neurogénica" y en donde por lo menos un antagonista de LHRH se va a administrar en una dosis intermedia, la cual no provoca castración química (hormonal).
MX2009009320A 2007-03-05 2008-03-05 Uso de antagonistas de lhrh para el tratamiento de sintomas del tracto urinario inferior, en particular vejiga hiperactiva y/o hiperactividad detrusora. MX2009009320A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89289907P 2007-03-05 2007-03-05
EP07103483A EP1967202A1 (en) 2007-03-05 2007-03-05 Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity
PCT/EP2008/052640 WO2008107446A1 (en) 2007-03-05 2008-03-05 Use of lhrh antagonists for the treatment of lower urinary tract symptoms, in particular overactive bladder and/or detrusor overactivity

Publications (1)

Publication Number Publication Date
MX2009009320A true MX2009009320A (es) 2009-09-10

Family

ID=38006763

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009009320A MX2009009320A (es) 2007-03-05 2008-03-05 Uso de antagonistas de lhrh para el tratamiento de sintomas del tracto urinario inferior, en particular vejiga hiperactiva y/o hiperactividad detrusora.

Country Status (13)

Country Link
US (1) US20090075937A1 (es)
EP (2) EP1967202A1 (es)
JP (1) JP2010520257A (es)
KR (1) KR20100014923A (es)
CN (1) CN101657211A (es)
AU (1) AU2008223841A1 (es)
BR (1) BRPI0808488A2 (es)
CA (1) CA2679690A1 (es)
IL (1) IL200182A0 (es)
MX (1) MX2009009320A (es)
RU (1) RU2009136642A (es)
WO (1) WO2008107446A1 (es)
ZA (1) ZA200905306B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2704298C (en) 2007-11-02 2015-07-21 Astellas Pharma Inc. Pharmaceutical composition for treating overactive bladder
TWI442932B (zh) 2008-02-11 2014-07-01 Ferring Int Ct Sa 以ＧｎＲＨ拮抗劑治療攝護腺癌的方法
EP2095818A1 (en) * 2008-02-29 2009-09-02 AEterna Zentaris GmbH Use of LHRH antagonists at non-castrating doses
US8778998B2 (en) 2009-04-10 2014-07-15 Auspex Pharmaceuticals, Inc. Biphenyl-3-carboxylic acid modulators of beta-3-adrenoreceptor
EP2424503B1 (en) 2009-05-01 2017-07-05 Ferring BV Composition for the treatment of prostate cancer
EP2266567A1 (en) * 2009-05-26 2010-12-29 Æterna Zentaris GmbH Use of cetrorelix in combination with PDE V inhibitors for the treatment of sex hormone dependent disorders
EP2266568A1 (en) * 2009-05-26 2010-12-29 Æterna Zentaris GmbH Use of LHRH antagonists in combination with PDE V inhibitors for the treatment of sex hormone dependent disorders
US20110039787A1 (en) * 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
KR20130135239A (ko) * 2010-08-03 2013-12-10 앨씨알엑스, 인크. 과민성 방광 치료를 위한 베타-3 아드레날린 수용체 작용제 및 무스카린 수용체 길항제의 약학적 배합제
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
US9522129B2 (en) 2010-08-03 2016-12-20 Velicept Therapeutics, Inc. Pharmaceutical Combination
PL2632934T3 (pl) 2010-10-27 2017-06-30 Ferring B.V. Sposób wytwarzania degareliksu i jego związków pośrednich
EP2447276A1 (en) 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
JO3755B1 (ar) 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
AR092840A1 (es) 2012-06-01 2015-05-06 Ferring Bv Elaboracion de degarelix
BR112015005351A2 (pt) 2012-09-18 2017-07-04 Taris Biomedical Llc sistemas para distribuição de drogas e métodos para tratamento de disfunção de esvaziamento da bexiga e outros distúrbios do trato urinário inferior
US9956194B2 (en) 2014-12-03 2018-05-01 Velicept Therapeutics, Inc. Compositions and methods of using modified release solabegron for lower urinary tract symptoms
PT3365321T (pt) 2015-10-23 2024-01-12 B3Ar Therapeutics Inc Zwiterião de solabegron e suas utilizações
BR112021001337A2 (pt) 2018-08-01 2021-04-20 Taris Biomedical Llc métodos de tratamento de bexiga hiperativa usando tróspio

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6054432A (en) * 1996-09-12 2000-04-25 Asta Medica Aktiengesellschaft Means for treating prostate hypertrophy and prostate cancer
NZ536787A (en) * 1998-06-11 2006-03-31 Endorech Inc Pharmaceutical compositions and uses for androst-5-ene-3beta,17beta diol
AU2001295359A1 (en) * 2000-10-30 2002-05-15 University Of Zurich GnRH analogues for treatment of urinary incontinence
RU2319692C2 (ru) * 2001-12-14 2008-03-20 Центарис Гмбх Производные тетрагидрокарбазола, способ получения производных тетрагидрокарбазола (варианты), их применение (варианты) и фармацевтическая композиция, обладающая активностью антагониста гонадотропин-рилизинг-гормона (варианты)
DE10164564B4 (de) * 2001-12-14 2007-05-16 Zentaris Gmbh Tetrahydrocarbazolderivate als Liganden für G-Protein gekoppelte Rezeptoren (GPCR)
GB0210397D0 (en) * 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
DE102004033902A1 (de) * 2004-07-14 2006-02-16 Zentaris Gmbh Neue Tetrahydrocarbazolderivate mit verbesserter biologischer Wirkung und verbesserter Löslichkeit als Liganden für G-Protein gekoppelte Rezeptoren (GPCR's)

Also Published As

Publication number Publication date
US20090075937A1 (en) 2009-03-19
IL200182A0 (en) 2010-04-15
EP1967202A1 (en) 2008-09-10
EP2131854A1 (en) 2009-12-16
CN101657211A (zh) 2010-02-24
AU2008223841A1 (en) 2008-09-12
JP2010520257A (ja) 2010-06-10
RU2009136642A (ru) 2011-04-10
WO2008107446A1 (en) 2008-09-12
BRPI0808488A2 (pt) 2014-07-15
ZA200905306B (en) 2010-04-28
KR20100014923A (ko) 2010-02-11
CA2679690A1 (en) 2008-09-12

Similar Documents

Publication Publication Date Title
MX2009009320A (es) Uso de antagonistas de lhrh para el tratamiento de sintomas del tracto urinario inferior, en particular vejiga hiperactiva y/o hiperactividad detrusora.
MX2010009447A (es) Uso de antagonistas de lhrh a dosis no castrantes.
Bai et al. Management of catheter-related bladder discomfort in patients who underwent elective surgery
Park et al. A randomized, double-blind trial of palonosetron compared with ondansetron in preventing postoperative nausea and vomiting after gynaecological laparoscopic surgery
IL207440A (en) Use of an antagonist antibody against a related peptide-calcitonin gene (cgrp) in the preparation of a drug for the prevention and / or treatment of chronic pain and / or symptoms of chronic pain and pharmaceutical preparations and kits containing it
WO2009021058A3 (en) Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy
WO2008050329A3 (en) Novel sirnas and methods of use thereof
NZ702485A (en) The use of inhibitors of bruton’s tyrosine kinase (btk)
MX2012010161A (es) Metodo para tratar el mal de parkinson.
TW200733975A (en) Pharmaceutical combination for the treatment of luts
MX2009009153A (es) Pirano-pirazol-aminas.
MY147391A (en) Treatment of chronic kidney disease (ckd) subjects using lanthanum compounds
MX2011011080A (es) Antagonistas de ccr3 de arilsulfonamida 2, 5-disustituida.
WO2008051496A3 (en) Use of il-1 antagonists to treat gout and pseudogout
JP2016505561A5 (es)
Chen et al. The chemokine CX3CL1/fractalkine interferes with the antinociceptive effect induced by opioid agonists in the periaqueductal grey of rats
EA201170873A1 (ru) Безопасное введение десмопрессина
WO2009124103A3 (en) Combination therapies comprising par1 antagonists with par4 antagonists
MX338130B (es) Compuestos de benzazepina.
Chen et al. The combination of morphine and minocycline may be a good treatment for intractable post-herpetic neuralgia
RU2016152226A (ru) Фармацевтический состав для уменьшения частоты мочеиспускания и способ его применения
Kus et al. Effect of combined administration of aripiprazole and fluoxetine on cognitive functions in female rats exposed to ethyl alcohol
WO2007074291A3 (fr) Derives de piperidine pour pour le traitement des incontinences
EP2164330A4 (en) SERCA2-BASED THERAPEUTIC COMPOSITIONS AND METHODS OF USE
WO2006124544A3 (en) Use of tyrosine kinase inhibitors in the treatment of metabolic disorders

Legal Events

Date Code Title Description
FA Abandonment or withdrawal